This man with ALS is “the first power user” of a brain implant that lets him speak

Casey Harrell has had a set of electrodes embedded in his brain for almost three years. Harrell, who has amyotrophic lateral sclerosis (ALS) and is paralyzed, first used his brain-computer interface (BCI) to “speak” sentences with the help of a research team in 2023.

Since then, Harrell has clocked thousands of hours of use. He can use the device largely independently, once he’s been “plugged in” with the help of a carer. His team has added new features to it, and Harrell also uses it to surf the web and perform his job.

“Living with a disease like ALS, you are supposed to have diminished dreams. I do not,” Harrell tells MIT Technology Review. “Any one of these things would be an absolute godsend of improvement. To have all of them, and many, many more, is truly revolutionary.” 

Within the first 22.6 months after the device was implanted, Harrell had used it for more than 3,800 hours at home without any researchers present, the team reported today in the journal Nature Medicine. “He’s the first power user of a speech BCI,” says team member Sergey Stavisky, a neuroengineer at the University of California, Davis.

Decoding speech

Three years ago, Harrell entrusted David Brandman, an associate professor of neurological surgery at the University of California, Davis, and his colleagues with his brain. Harrell, who was 45 at the time, had already been diagnosed with ALS, a degenerative disease that robs people of the use of their muscles.

Harrell was dependent on others to control his wheelchair and to dress and feed him. He had difficulty speaking; people struggled to understand what he was saying. Then Brandman and his colleagues asked if he’d like to trial a brain implant that might help him communicate. “The industry was [on the] cusp of a transformation, and I wanted to be part of it,” says Harrell. He signed up.

In July 2023, during a five-hour operation, doctors implanted four arrays of 64 electrodes each into his brain. Each pair of arrays was wired to a “pedestal” connection point—creating two docking locations on the exterior of his skull to connect the electrodes to a computer.

The team had long been working on developing algorithms to decode brain activity into speech. Their system works by recording activity from the speech motor cortex—a region of the brain responsible for the movements that allow us to speak.

“There are 39 phonemes that make up all the sounds in the [American] English language,” says Nicholas Card, a neuroengineer at UC Davis and member of the team. Mapping neural activity related to producing each of those phonemes can allow the team to create a personalized speech decoder and software that can “speak” those words. “We first go from brain data to phonemes, and then from phonemes to words,” he says.

They started using the device around a month after the surgery. The team got Harrell’s speech decoder working on the first day, says Card. On that day in August, Harrell used the device to speak with a 50-word vocabulary, and 99.6% of the words were as he’d intended. That vocabulary was later expanded to 125,000 words with 97.5% accuracy.

At the time, it was unclear how long the device might last. Brain-computer interfaces are still new—not many people have had them implanted for long periods of time. Scar tissue can form around electrodes in a person’s brain, interfering with their ability to pick up neural activity, for example. But that doesn’t seem to be the case for Harrell.

Power user

In another advance, Harrell is now able to use the device more independently. In 2023, members of the research team would have to visit Harrell at his home and physically connect and disconnect him from the device on the days he wanted to use it. Not anymore. The team has since automated more of the system—today, Harrell’s care partner can don and doff it for him. “He’ll wake up, get plugged in, and just get going,” says Stavisky.

This is important, says Mariska Vansteesel, a BCI researcher at Utrecht Medical Center who was not involved in the trial. “For these technologies to be relevant for patients, we really need to test them in settings in which they will eventually be used … to demonstrate that it has value, that it’s usable, and that it functions well without the constant involvement of a research team,” she says.

Casey Harrell uses his BCI to speak in “private mode.”

The team has also worked to improve the system itself. It is now 99% accurate, says Stavisky. Harrell can also control a cursor—a game changer that enables him to use his personal computer to send text messages and emails, surf the web, and keep up with his job as an environmental activist.

Over the years, the team has updated the system to accommodate specific requests from Harrell. He is now able to switch on a “privacy mode”—when active, any decoded text will be automatically deleted. He can also opt to use a “profanity filter” while he’s talking to his young daughter.

“We have been able to add on to the software side of the device … improving the accuracy and adding more bells and whistles to enable me to be more independent when using the device,” says Harrell. “We are making the road as we walk it, or roll it, so to speak.”

Nothing short of revolutionary

Vansteesel cautions that while the device is working well for Harrell, there’s no guarantee it will work as well, or as long, for other people with ALS. Over the last decade, she has worked with a woman with ALS who used a fully implanted device to communicate using “brain clicks”—cursor clicks made using brain activity. The woman used her BCI for seven years, but it stopped working toward the end of that period, apparently due to brain degeneration.

At any rate, not everyone with ALS will be willing to undergo invasive brain surgery, says Jane Huggins, who is developing noninvasive BCIs at the University of Michigan and was not involved in the trial. “Long-term, independent use with efficient and accurate communication is kind of the holy grail of BCI,” she says. “But we have been finding a consistent aversion to hospital stays among people with progressive conditions like ALS.”

Harrell, however, calls the device “nothing short of revolutionary.” “This has allowed me to keep working and earn money and insurance for my family. This is reconnecting me with friends and family who are too shy or too afraid to come over and not be able to understand me,” Harrell says. “With my seven-year-old daughter, I am able to create a bond that I wasn’t before able to forge. Now I can read to them and help them sharpen their own reading skills. By doing so, I am able to share the responsibility of parenting with my wife, who does so much caregiving for me and also our daughter.”

Stavisky and his colleagues hope to improve the device further still. “We’re never satisfied,” he says. One aim is to eventually restore Harrell’s “full voice.” They are working on a “brain-to-voice” system that could directly decode brain activity to a speaking voice, complete with natural-sounding cadence, inflection and intonation—a voice that could sound happy, angry, or sarcastic, for example.

“I was quietly confident that I could get some personal benefit from the system,” says Harrell. “Never in a million years would I think that I would achieve this much.” 

STAT+: A key European clinical trial registry lacks complete and timely results, an analysis finds

Amid ongoing concern about clinical trial transparency, a new analysis found that results for less than half of the studies registered in a key European database were reported within the required time frame and complete results were fully reported for only 42%.

While the quality of the registration data was high overall — more than 99% of expected data was found in the 234 clinical trials for which results were supposed to have been disclosed — the researchers contended that overall compliance with legal reporting requirements was weak and regulatory oversight is lacking.

European Union and member state regulators “have so far not delivered the promised ‘high levels of transparency never seen before for clinical trials,’” the authors wrote in their analysis. It was recently posted on the medRxiv preprint server, which displays unpublished research that has not yet been peer reviewed.

Continue to STAT+ to read the full story…

Covid vaccination cut risk of adverse heart events, large study finds

Recent Covid vaccination appears to have broad cardioprotective effects, according to a new study, which found reduced risk of events like heart attacks and stroke, hospitalization, and death in people who had received the vaccine. 

The study, published in JAMA Internal Medicine on Monday along with several other Covid-related papers, followed more than 1 million veterans who received flu vaccinations at Veterans Affairs health care facilities in 2024; about a third of them also received a Covid vaccine. 

Read the rest…

<![CDATA[Teens’ pre-bed smartphone scrolling drives more late-night phone use, disrupting sleep and potentially worsening mental health—experts urge bedtime screen limits and device-free bedrooms.]]>

STAT+: Lilly’s Ajax acquisition may have been worth it

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

A worsening shortage of Bicillin, Pfizer’s injectable form of penicillin, left an Arizona woman unable to receive timely treatment for syphilis during pregnancy.

Also, the FDA approved Sanofi’s diabetes drug Tzield after an unusually contentious review process, and the Trump administration has proposed closing a Medicare negotiation loophole.

Continue to STAT+ to read the full story…

The Download: cutting AC emissions, and nature’s drug designer

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.

These new solid-state ACs promise a cool future. Scientists aren’t so sure.

After three years of record-­breaking heat and another scorcher underway, air-conditioning isn’t going anywhere. That’s good for our health, but bad for the planet: it already accounts for 7% of global electricity use and 3% of greenhouse-gas emissions. 

Feeling the heat, scientists and startups are hoping to amp up solid-­state cooling. These systems move heat through conductive materials, which could cool spaces and surfaces with fewer messy side effects. The catch is whether it can match the efficiency of traditional AC.

Find out how the unconventional coolers aim to dial down AC emissions.

—Sara Kiley Watson


This story is from the next edition of our magazine, which is all about engineering.
Subscribe now to get a copy when it lands! 

Job titles of the future: nature’s drug designer

In 2018, after nearly two decades working in Big Pharma, chemist Tim Cernak was ready to put his skills to a new use. 

As a lifelong nature lover, he had become concerned that animals are often treated with human pharmaceuticals that can be harmful or even lethal. He decided to address this with a new approach: “conservation chemistry.” 

Using AI tools and robots, he’s now rapidly designing and testing drugs for animals. Here’s what it takes to treat nature’s patients.

—Anna Gibbs

The must-reads

I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology.

1 Anthropic has shut down access to its top models after a US directive
The US barred foreigners from using Fable 5 and Mythos 5 on Friday. (NYT $)
+ Anthropic disabled access globally as it can’t filter users in real time.(BBC)
+ Talks with Amazon’s CEO apparently prompted the ban. (WSJ $)
+ Cybersecurity experts have called for the ban to end. (Axios)
+ But the White House’s war against Anthropic has previously backfired.
(MIT Technology Review)

2 The UK is banning social media for under-16s
Details are scant, but the measure is due to take effect in early 2027. (The Guardian)
+ The ban covers Snapchat, TikTok, YouTube, Instagram, Facebook, and X. (BBC)
+ Many countries are curbing children’s social media access. (Reuters $)

3 New space data suggests black holes formed before galaxies
It could resolve cosmology’s chicken-and-egg dilemma. (New Scientist $)
+ Odd tricks have formed a massive black hole. (MIT Technology Review)

4 Skepticism around AI layoffs is increasing
There are growing doubts that AI is really the culprit. (TechCrunch)
+ We need a reality check on AI jobs hysteria. (MIT Technology Review)

5 A coalition of states has opened an investigation into OpenAI
Over matters including user data, child safety and advertising. (NYT $)

6 Tesla has been accused of misleading regulators over “full self-driving”
By exaggerating its safety statistics. (Reuters $)

7 NASA’s “quiet supersonic” plane has hit critical new milestones
The X-59 reached 924 mph and 55,000 feet. (Scientific American
+ Which are essential for flying over populated areas. (Engadget)
+ It’s designed to take the boom out of supersonic travel. (BBC)

8 Deepfakes are getting harder to spot—and weirder—in the midterms
Thanks to improvements in free AI tools. (WSJ $)

9 AI is revealing the secret lives of animals
By tracing their movements, landmarks, and social practices. (Nature

10 Where did Earth get its oceans? Maybe it made them itself.
Scientists now suspect that Earth’s waters are homegrown. (Quanta

Quote of the day

“This action has taken the best models away from defenders, created market uncertainty, and risked America’s AI leadership without any real risk to justify it.” 

—Cybersecurity leaders urge the Trump administration to reverse restrictions on Anthropic’s most advanced AI models in an open letter.

One More Thing

CHRISTIE HEMM KLOK


How scientists want to make you young again

A little over 15 years ago, scientists at Kyoto University made a remarkable discovery. When they added just four proteins to a skin cell and waited about two weeks, some of the cells underwent an unexpected and astounding transformation: they became young again.

Now, after more than a decade of developing this cellular reprogramming, biotech companies and research labs have tantalising hints that the process could be the gateway to an unprecedented new technology for human age reversal. 

Read the full story on their efforts to “reprogram” aging bodies back to youth.
 

—Antonio Regalado

We can still have nice things

A place for comfort, fun, and distraction to brighten up your day. (Got any ideas? Drop me a line.)

+ Evolutionary biologists may have figured out why the T-Rex had such tiny arms.
+ This beautifully sustainable bento box design is engineered to eliminate single-use takeout waste.
+ Search across 5.8 million museum artworks spanning from 3000 BC to today at The Last Museum.
+ Here’s a sharp cosmic snapshot of Thor’s Helmet, an interstellar gas bubble sitting 15,000 light-years away.

A novel de novo QRICH1 variant causing Ververi–Brady syndrome with infantile epileptic spasms syndrome: clinical and genetic analysis

ObjectiveThis study aims to investigate the clinical phenotype and genetic etiology of a case of Ververi–Brady syndrome (VBS) with infantile epileptic spasms syndrome (IESS) caused by a novel de novo variant in the QRICH1 gene.MethodsClinical data were retrospectively collected from a pediatric patient admitted to Hunan Children’s Hospital on July 28, 2025, due to intermittent nodding episodes for 10 days. Trio-based whole-exome sequencing (trio-WES) was performed for the proband and his parents. Candidate variants were validated by Sanger sequencing and assessed for pathogenicity. Relevant literature was reviewed to summarize genotype–phenotype correlations.ResultsThe patient, a 5-month-and-22-day-old male infant, presented with facial dysmorphism, global developmental delay, and IESS. After treatment with adrenocorticotropic hormone (ACTH) and vigabatrin, seizures were fully controlled and developmental outcomes improved. Trio-WES identified a novel heterozygous frameshift variant in the QRICH1 gene (NM_198880.3: c.1282dup, p. Gln428Profs*27), which was de novo and absent in both parents. According to the ACMG/AMP guidelines, this variant was classified as pathogenic (PVS1 + PS2 + PM2_Supporting). A literature review identified 11 relevant articles, encompassing a total of 46 patients (including the present case) with 41 distinct QRICH1 variants: 10 missense, 11 nonsense, 17 frameshift, and 3 splicing mutations. Common clinical features included developmental delay, nonspecific facial dysmorphism, hypotonia, autism spectrum disorder, epilepsy, and scoliosis.ConclusionQRICH1 variants underlie Ververi–Brady syndrome. Here we describe a patient with QRICH1-related Ververi–Brady syndrome presenting with IESS. Combined treatment with ACTH and vigabatrin was followed by seizure freedom, electroencephalographic (EEG) improvement, and developmental gains in this patient. This report expands the genotypic and phenotypic spectrum of the disorder.

Spatial transcriptomics on an expanded dataset at the brain-electrode interface: exploration of variability and identification of novel biomarkers

The foreign body reaction to implanted electrodes in the brain has long been recognized as a major challenge impacting the performance and reliability of indwelling neurotechnologies. Spatially resolved transcriptomic approaches have enabled high-resolution mapping of cellular and molecular dynamics at the device-tissue interface, yielding novel insight into both acute and chronic tissue responses. Recent whole-transcriptome profiling methods generate exceptionally dense gene expression datasets from individual samples, offering unprecedented resolution and analytical power. Yet, limited studies have explored aggregated results from larger datasets and sample-to-sample variation within an implanted cohort using such techniques due to high costs and complicated downstream analyses. In this work, we provide a comprehensive report of spatial transcriptomics data collected from an expanded cohort of rats (n = 14 rats) implanted with silicon microelectrode arrays in the motor cortices for 1 week (acute) and 6 weeks (chronic). This larger dataset enabled us to explore the variation in results across samples, assess outliers, and examine potential batch effects. We employed differential expression analysis to identify top differentially expressed genes (DEGs) in spatially defined regions at the device-tissue interface to reveal novel biomarkers in the aggregated dataset. We assessed sample-to-sample variabilities, and applied a factorization strategy to identify prominent cell-type contributors of the top DEGs. Using network-based co-expression analysis, we identified gene modules, hub genes, and central regulatory processes governing the device-tissue interface. Our results show: (a) greater variation of top DEGs across samples at the 1-week time point with notable microglial and astroglial cell-type contributors, (b) lower variation of top DEGs across samples and a shift to prominent astroglial cell-type contributors at the 6-week time point, and (c) novel biomarkers that suggest major macrophage- and microglial mediated processes and homeostasis events at the 1-week time point, and greater tissue remodeling, apoptotic and synaptic changes at the 6-week time point. These findings support previous ideas on the evolving tissue response to implanted devices, and present novel details on biomarkers, biological processes and sample variation. Additionally, this study provides a framework for assessing larger datasets employing high-dimensional spatial transcriptomics and highlight key considerations related to across-sample variability and batch effects.

Sex-divergent intrinsic brain function in Parkinson’s disease: elevated nigral fluctuations and premotor-visuospatial coupling in female patients

IntroductionCortical and subcortical alterations in brain intrinsic function have been widely reported in Parkinson’s disease (PD). However, sex differences in brain intrinsic function in PD are poorly understood. This study aimed to examine sex differences in spontaneous brain intrinsic function in PD and their associations with neuropsychological measurements.MethodsUsing Parkinson’s Progression Markers Initiative (PPMI) resting-state fMRI, we compared amplitude of low-frequency fluctuations (ALFF) between male and female PD patients in substantia nigra (SN), globus pallidus (GP) and whole-brain. Subgroup analysis was performed, matching demographics with equal sample sizes. ALFF correlations with behavior were assessed by sex.ResultsFemale PD patients demonstrated higher ALFF in the right SN compared to males in the primary analysis. This sex difference achieved statistical significance in the demographics-matched subgroup analysis. Bilateral premotor ALFF was significantly elevated in female patients relative to males, independent of brain structure. Furthermore, right premotor ALFF showed a preliminary positive trend associated with visuospatial function exclusively in female PD patients.ConclusionFemale PD patients exhibit distinct functional signatures, primarily involving elevated premotor fluctuations and a preliminary premotor-visuospatial association. Preliminary SN alterations were also noted. These findings highlight the necessity of sex-stratified neuroimaging and provide preliminary support for premotor ALFF as a potential sex-divergent functional signature associated with cognitive profiling in female patients with PD.

Developmental outcomes of young children with an autism diagnosis and its associated clinical correlates

IntroductionAutism spectrum disorder is common in children with increasing prevalence, leading to efforts towards early identification and treatment initiation in young children. We aimed to identify the developmental trajectory of young children with an autism diagnosis and clinical factors associated with better developmental outcomes in a real-world setting.MethodsIn this study, 38 children (mean age 21.9 ± 4.7 months) who were diagnosed at < 2 years of age with autism had developmental evaluations using the Mullen Scales of Early Learning done at baseline and after 1–2 years post diagnosis and intervention initiation.ResultsIn the sample, improvements in T-scores were observed for Receptive Language (mean 26.5 to 32.0, p=0.003) and Expressive Language (mean 26.0 to 30.7, p=0.010) at the group level, while Visual Reception, Fine Motor and overall Early Learning Composite did not change significantly at follow-up. Higher baseline T-scores were consistently associated with better follow-up scores across Fine Motor, Receptive Language, Expressive Language and Early Learning Composite domains. Age at initial presentation was significantly associated with Fine Motor outcomes (β = 1.26, p=0.031) while intervention hours were not independently associated with any developmental domain outcomes in the full sample. Among children with baseline developmental delay, higher intervention hours were associated with better follow-up scores in Receptive as well as Expressive Languages and Visual Reception; this was not seen for the entire sample.ConclusionsOur results support the role of early identification and intervention for autism; however, child-level characteristics influence developmental trajectories beyond intervention hours alone.